Clinical trials: Novel Coronavirus Pneumonia
COVID-19
Phase 2/3 Heterologous Boosting Study With Different Dose Levels of Monovalent SARS-CoV-2 rS Vaccines
This is a Phase 2/3, randomized, double-blind study to evaluate the safety and immunogenicity of different booster dose levels of the monovalent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) recombinant (r) spike…
- Trial name
- COVID-19 (NCT05925127)
- Testing
- NVX-CoV2373 (5μg), NVX-CoV2601 (5μg), NVX-CoV2601(5μg)
- Where
- 50 sites in United States
- Volunteers
- 994 people, healthy volunteers welcome
- Sponsor
- Novavax
SARS-CoV Infection, Covid19
A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults ≥ 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2
This is a phase 3, randomized, observer-blinded, placebo-controlled study to evaluate the efficacy, safety, and immunogenicity of SARS-CoV-2 rS with Matrix-M1 adjuvant in adult participants and adolescent participants.
- Trial name
- NCT04611802
- Testing
- SARS-CoV-2 rS/Matrix-M1 Adjuvant (Initial Vaccination Period), SARS-CoV-2 rS/Matrix-M1 Adjuvant (Crossover Vaccination period), SARS-CoV-2 rS/Matrix-M1 Adjuvant (Booster Vaccination)
- Where
- 154 sites in United States, Mexico and 1 more
- Volunteers
- 33,000 people, healthy volunteers welcome
- Sponsor
- Novavax
Pulmonary Infection, Covid-19
Triiodothyronine for the Treatment of Critically Ill Patients With COVID-19 Infection
This study is a phase II, parallel, prospective, randomized, double-blind, placebo controlled trial. The present study will aim to address the efficacy and safety of acute administration of triiodothyronine on ICU patients…
- Trial name
- Thy-Support (NCT04348513)
- Testing
- T3 solution for injection
- Where
- Greece
- Volunteers
- 5 people
- Sponsor
- Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A.
SARS-CoV-2 Infection, COVID-19
Safety, Tolerability and Efficacy of Molnupiravir (EIDD-2801) to Eliminate Infectious Virus Detection in Persons With COVID-19
This was a phase IIa, double-blind, placebo-controlled, randomized trial, designed to compare the safety, tolerability, and antiviral activity of EIDD-2801 (molnupiravir) versus placebo as measured by SARS-CoV-2 viral RNA…
- Trial name
- NCT04405570
- Testing
- Molnupiravir 200 mg, Molnupiravir 400 mg, Molnupiravir 800 mg
- Where
- 10 sites in United States
- Volunteers
- 204 people
- Sponsor
- Ridgeback Biotherapeutics, LP
COVID-19, SARS-CoV-2 Infection
A Study to Evaluate the Immunogenicity and Safety of a Recombinant Protein COVID-19 Vaccine SCTV01E-1 in Population Aged Above 18 Years
The study is a randomized, double-blind Phase II study. It will evaluate the immunogenicity and safety of SCTV01E-1. Approximately 400 participants aged 18 years and older will be enrolled in this study.
- Trial name
- NCT05522829
- Testing
- SCTV01E-1 on D0, SCTV01E-1 on D28, SCTV01E-1 on D150
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Sinocelltech Ltd.
Long COVID, Post COVID-19 Condition
Investigating the Effectiveness of Vimida
This randomized controlled trial (RCT) with 160 patients suffering from fatigue after COVID-19 infection aims to investigate the effectiveness of the unguided digital therapeutic vimida for reducing post-COVID-19 fatigue.
- Trial name
- InvidiCO (NCT06251518)
- Testing
- vimida
- Where
- Germany
- Volunteers
- 160 people
- Sponsor
- Gaia AG
COVID-19
Immunogenicity and Safety of COVID-19 Vaccine in Population Aged 18 Years and Above
This is a randomized, blinded, positive-controlled study to evaluate the immunogenicity and safety of Recombinant SARS-CoV-2 Vaccine (CHO Cell) LYB001, in population aged 18 years old and above（negative antibody against…
- Trial name
- NCT05663086
- Testing
- One dose group, Two doses group, Aged 18-59 years
- Where
- China
- Volunteers
- healthy volunteers welcome
- Sponsor
- Guangzhou Patronus Biotech Co., Ltd.
COVID-19
Study of Efficacy and Safety of TL-FVP-t vs. SOC in Patients With Mild to Moderate COVID-19
Randomized open-label multicenter parallel-group study of efficacy and safety of TL-FVP-t vs. standard of care therapy in patients with mild to moderate coronavirus disease (SARS-CoV-2/COVID-19)
- Trial name
- NCT04501783
- Testing
- Favipiravir, Standard of care (SOC), standard concomitant therapy
- Where
- 10 sites in Russia
- Volunteers
- 168 people
- Sponsor
- R-Pharm
COVID-19
A Study to Understand is the COVID-19 Vaccine BNT162b2 is Safe in Indonesia People
The purpose of this study is to characterize descriptively the BNT162b2 vaccination safety experience among the Indonesian people.
- Trial name
- NCT05621239
- Testing
- BNT162b2
- Where
- Indonesia
- Volunteers
- 260 people
- Sponsor
- Pfizer
COVID-19
A Study of S-892216 in Participants With COVID-19
The primary objective of this study is to investigate the antiviral effect of S-892216 in participants with coronavirus disease 2019 (COVID-19) due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.
- Trial name
- NCT06928051
- Testing
- S-892216
- Where
- 57 sites in United States, Japan
- Volunteers
- 282 people
- Sponsor
- Shionogi
COVID-19, Coronavirus Infections
Safety, Tolerability, and Immunogenicity of Trivalent Coronavirus Vaccine Candidate VBI-2901e With E6020 Adjuvant
VBI-2901e is an investigational vaccine candidate that uses enveloped virus-like particles (eVLPs) to express the spike proteins of three coronaviruses: SARS-CoV-2 (the virus that causes COVID-19 disease), SARS-CoV-1 and…
- Trial name
- NCT05614245
- Testing
- VBI-2901e
- Where
- 4 sites in Canada
- Volunteers
- healthy volunteers welcome
- Sponsor
- VBI Vaccines Inc.
COVID-19
Pilot Clinical Trial to Explore Efficacy and Safety of Pyramax in Mild to Moderate COVID-19 Patients
This study is a multi-center, single-arm, open-label, pilot clinical trial to explore efficacy and safety of Pyramax in mild to moderate COVID-19 patients
- Trial name
- NCT05633420
- Testing
- Pyramax
- Where
- 2 sites in South Korea
- Volunteers
- 20 people
- Sponsor
- Shin Poong Pharmaceutical Co. Ltd.
SARS-CoV-2, Influenza, Human
Study on Safety and Efficacy of Two Doses of PRS CK STORM in the Modulation of the Cytokine Storm in Patients With Acute Respiratory Infection Caused by SARS-Cov-2, Influenza A, Influenza B and Respiratory Syncytial Virus (RSV)
The purpose of this clinical trial is to evaluate the safety, tolerability and efficacy of two doses (dose A and dose B) of Standardized Conditioned Medium Obtained by Coculture of M2-macrophages and fat-derived Mesenchymal…
- Conditions
- SARS-CoV-2, Influenza, Human, Respiratory Syncytial Virus Infections, Respiratory Distress Syndrome
- Trial name
- NCT06684379
- Testing
- PRS CK STORM
- Where
- 3 sites in Spain
- Volunteers
- 50 people
- Sponsor
- PEACHES BIOTECH
COVID-19 Pneumonia
Evaluation of Immunogenicity and Safety of COVID-19 Vaccine (Produced in Beijing) in Patients With Hypertension and/or Diabetes
To evaluate the post-marketing immunogenicity and safety of the inactivated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine (Vero cells) in patients aged 60 years or older with hypertension and/or diabetes…
- Trial name
- NCT05065879
- Testing
- COVAX
- Where
- 5 sites in China
- Volunteers
- 1,440 people, healthy volunteers welcome
- Sponsor
- China National Biotec Group Company Limited
Hepatic Impairment
Study to Estimate the Effects of Hepatic Impairment on the Pharmacokinetics (PK) of PF-07321332
The study is to estimate the effect of hepatic impairment on the plasma PK of PF-07321332/ritonavir. Findings from this study will be used to develop dosing recommendations so that the dose and/or dosing interval may be adjusted…
- Trial name
- NCT05005312
- Testing
- PF-07321332, Ritonavir
- Where
- 2 sites in United States
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- Pfizer
COVID-19, SARS-CoV-2
To Evaluate SCTA01 Treatment of High-risk Outpatients With COVID-19
The study is a multicenter, adaptive, randomized, double-blinded and placebo-controlled Phase II/III clinical trial. It will be conducted at selected investigational sites globally. The study is comprised of 2 parts.
- Trial name
- MAOP3 (NCT04709328)
- Testing
- SCTA01
- Volunteers
- 690 people
- Sponsor
- Sinocelltech Ltd.
SARS-CoV-2, COVID-19
A Study on the Safety and Immune Response of Investigational COVID-19 mRNA Vaccines in Healthy Adults
The purpose of Part A of this study is to assess the immune response and safety of a booster dose of investigational COVID-19 mRNA vaccines in healthy adults.
- Trial name
- NCT05960097
- Testing
- CV0701 mRNA COVID-19 Vaccine (Low dose), CV0701 mRNA COVID-19 Vaccine (Medium dose), CV0701 mRNA COVID-19 Vaccine (High dose)
- Where
- 17 sites in United States, Australia
- Volunteers
- 692 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
COVID-19, Coronavirus
Safety and Efficacy of Rayaldee for Treating Mild to Moderate COVID-19
This is a phase 2, single or multi-center, randomized, double-blind placebo-controlled study to evaluate the safety and efficacy of Rayaldee (CTAP101 Capsules) to treat adult subjects with mild to moderate COVID-19 who test…
- Conditions
- COVID-19, Coronavirus, SARS-CoV2 Infection
- Trial name
- NCT04551911
- Testing
- Rayaldee
- Where
- 10 sites in United States
- Volunteers
- 171 people
- Sponsor
- OPKO Health, Inc.
COVID-19, SARS-CoV-2
Study to Assess Safety, Reactogenicity and Immunogenicity of the repRNA(QTP104) Vaccine Against SARS-CoV-2(COVID-19)
This study is to evaluate the safety, reactogenicity, and immunogenicity of the QTP104 vaccine against SARS-CoV-2 infection in healthy adults.
- Trial name
- NCT05876364
- Testing
- QTP104 1ug, QTP104 5ug, QTP104 25ug
- Where
- 2 sites in South Korea
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Quratis Inc.
COVID-19 Pneumonia
Evaluation of Immunogenicity, Safety and Antibody Persistence of COVID-19 Booster Vaccine (Produced in Wuhan) in Patients With Hypertension and/or Diabetes
To evaluate the post-marketing immunogenicity, safety and antibody persistence of the third dose (booster) of Covid-19 vaccine in patients aged 60 years or older with hypertension and/or diabetes.
- Trial name
- NCT05104437
- Testing
- Covid-19 vaccine (0-1-4 schedule), Covid-19 vaccine (0-1-6 schedule)
- Where
- 3 sites in China
- Volunteers
- 1,440 people, healthy volunteers welcome
- Sponsor
- China National Biotec Group Company Limited